Christopher I. Murray

Christopher I. Murray

Auto-generated profile, based on publicly available information

Christopher I. Murray

Cedars‐Sinai Medical Center Los Angeles CA USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Physiological Reviews
Verified
Journal Article
Open access
OKOleg A. Karpov
Oleg A. Karpov
ASAleksandr Stotland
Aleksandr Stotland
KRKoen Raedschelders
Koen Raedschelders
BCBlandine Chazarin
Blandine Chazarin
LALizhuo Ai
Lizhuo Ai
JEJennifer Van Eyk
Jennifer Van Eyk
Mass spectrometry-based proteomics is a sophisticated identification tool specializing in portraying protein dynamics at a molecular level. Proteomics provides biologists with a snapshot of context-dependent protein and proteoform expression, structural conformations, dynamic turnover, and protein-protein interactions. Cardiac proteomics can offer a broader and deeper understanding of the molecular mechanisms that underscore cardiovascular disease, and it is foundational to the development of future therapeutic interventions. This review encapsulates the evolution, current technologies, and future perspectives of proteomic-based mass spectrometry as it applies to the study of the heart. Key technological advancements have allowed researchers to study proteomes at a single-cell level and employ robot-assisted automation systems for enhanced sample preparation techniques, and the increase in fidelity of the mass spectrometers has allowed for the unambiguous identification of numerous dynamic posttranslational modifications. Animal models of cardiovascular disease, ranging from early animal experiments to current sophisticated models of heart failure with preserved ejection fraction, have provided the tools to study a challenging organ in the laboratory. Further technological development will pave the way for the implementation of proteomics even closer within the clinical setting, allowing not only scientists but also patients to benefit from an understanding of protein interplay as it relates to cardiac disease physiology.

1 March 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SKShathiyah Kulandavelu
Shathiyah Kulandavelu
RDRaul Dulce
Raul Dulce
CMChristopher I. Murray
Christopher I. Murray
MBMichael A. Bellio
Michael A. Bellio
JFJulia Fritsch
Julia Fritsch
JHJoshua M. Hare
Joshua M. Hare
Background: Preeclampsia, a leading cause of maternal and fetal mortality and morbidity, is characterized by an increase in S‐nitrosylated proteins and reactive oxygen species, suggesting a pathophysiologic role for dysregulation in nitrosylation and nitrosative stress. Methods and Results: Here, we show that mice lacking S‐nitrosoglutathione reductase ( GSNOR −⁄− ), a denitrosylase regulating protein S‐nitrosylation, exhibit a preeclampsia phenotype, including hypertension, proteinuria, renal pathology, cardiac concentric hypertrophy, decreased placental vascularization, and fetal growth retardation. Reactive oxygen species, NO, and peroxynitrite levels are elevated. Importantly, mass spectrometry reveals elevated placental S‐nitrosylated amino acid residues in GSNOR −⁄− mice. Ascorbate reverses the phenotype except for fetal weight, reduces the difference in the S‐nitrosoproteome, and identifies a unique set of S‐nitrosylated proteins in GSNOR −⁄− mice. Importantly, human preeclamptic placentas exhibit decreased GSNOR activity and increased nitrosative stress. Conclusions: Therefore, deficiency of GSNOR creates dysregulation of placental S‐nitrosylation and preeclampsia in mice, which can be rescued by ascorbate. Coupled with similar findings in human placentas, these findings offer valuable insights and therapeutic implications for preeclampsia.

22 September 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
QFQin Fu
Qin Fu
PRPhilip M. Remes
Philip M. Remes
JLJihyeon Lee
Jihyeon Lee
CJCristina Jacob
Cristina Jacob
DLDalin Li
Dalin Li
JEJennifer E. Van Eyk
Jennifer E. Van Eyk
Despite advances in clinical proteomics, translating protein biomarker discoveries into clinical use remains challenging due to the technical complexity of the validation process. Targeted MS‐based proteomic approaches such as parallel reaction monitoring (PRM) offer sensitive and specific assays for biomarker translation. In this study, we developed a multiplex PRM assay using the Stellar mass spectrometry platform to quantify 57 plasma proteins, including 24 FDA‐approved biomarkers. Loading curves (11 points) were performed at 4 sample throughputs (100, 144, 180, and 300 samples per day) using independently optimized and scheduled PRM methods. Following optimization, an inflammatory bowel disease (IBD) cohort of plasma samples (493 IBD, 509 matched controls) was analyzed at a throughput of 180 samples per day. To monitor system performance, the study also included over 1000 additional injections for system suitability tests, low‐, middle‐, and high‐quality controls, washes, and blanks. Using this approach, we observed high quantifiability (linearity, sensitivity, and reproducibility) in the PRM assay and consistent data acquisition across a large cohort. We also validated the candidate IBD markers, C‐reactive protein and orosomucoid protein, identified in a recent discovery experiment.

21 September 2025 in Angewandte Chemie
Verified
Journal Article
Open access
QFQin Fu
Qin Fu
PRPhilip M. Remes
Philip M. Remes
JLJihyeon Lee
Jihyeon Lee
CJCristina Jacob
Cristina Jacob
DLDalin Li
Dalin Li
JEJennifer E. Van Eyk
Jennifer E. Van Eyk
Despite advances in clinical proteomics, translating protein biomarker discoveries into clinical use remains challenging due to the technical complexity of the validation process. Targeted MS‐based proteomic approaches such as parallel reaction monitoring (PRM) offer sensitive and specific assays for biomarker translation. In this study, we developed a multiplex PRM assay using the Stellar mass spectrometry platform to quantify 57 plasma proteins, including 24 FDA‐approved biomarkers. Loading curves (11 points) were performed at 4 sample throughputs (100, 144, 180, and 300 samples per day) using independently optimized and scheduled PRM methods. Following optimization, an inflammatory bowel disease (IBD) cohort of plasma samples (493 IBD, 509 matched controls) was analyzed at a throughput of 180 samples per day. To monitor system performance, the study also included over 1000 additional injections for system suitability tests, low‐, middle‐, and high‐quality controls, washes, and blanks. Using this approach, we observed high quantifiability (linearity, sensitivity, and reproducibility) in the PRM assay and consistent data acquisition across a large cohort. We also validated the candidate IBD markers, C‐reactive protein and orosomucoid protein, identified in a recent discovery experiment.